These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26492961)

  • 1. Chronic pain: the burden of disease and treatment innovations.
    Monti S; Caporali R
    Reumatismo; 2015 Oct; 67(2):35-44. PubMed ID: 26492961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current considerations for the treatment of severe chronic pain: the potential for tapentadol.
    Pergolizzi J; Alegre C; Blake D; Alén JC; Caporali R; Casser HR; Correa-Illanes G; Fernandes P; Galilea E; Jany R; Jones A; Mejjad O; Morovic-Vergles J; Oteo-Álvaro Á; Radrigán Araya FJ; Simões ME; Uomo G
    Pain Pract; 2012 Apr; 12(4):290-306. PubMed ID: 21797962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapentadol - A representative of a new class of MOR-NRI analgesics.
    Zajączkowska R; Przewłocka B; Kocot-Kępska M; Mika J; Leppert W; Wordliczek J
    Pharmacol Rep; 2018 Aug; 70(4):812-820. PubMed ID: 29921501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unique pharmacology of tapentadol for treating acute and chronic pain.
    Knezevic NN; Tverdohleb T; Knezevic I; Candido KD
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1475-92. PubMed ID: 26215077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tapentadol prolonged release in the treatment of musculoskeletal pain: an innovative pharmacological option.
    Marinangeli F; Evangelista M; Finco G
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):5-13. PubMed ID: 31755079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview].
    Tzschentke TM; Christoph T; Schröder W; Englberger W; De Vry J; Jahnel U; Kögel BY
    Schmerz; 2011 Feb; 25(1):19-25. PubMed ID: 21258822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tapentadol for pain: a treatment evaluation.
    Hartrick CT; Rodríguez Hernandez JR
    Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
    Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
    Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapentadol prolonged release and the long-term management of chronic musculoskeletal pain in the elderly - focus on anxiety, depression, cognitive status and life quality: the TaPE study.
    Tarsitano A; Cortese M; Barile M; Scarpelli P
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):35-39. PubMed ID: 31755081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapentadol: an analgesic that differs from classic opioids due to its noradrenergic mechanism of action.
    Caputi FF; Nicora M; Simeone R; Candeletti S; Romualdi P
    Minerva Med; 2019 Feb; 110(1):62-78. PubMed ID: 30667206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice.
    Kögel B; De Vry J; Tzschentke TM; Christoph T
    Neurosci Lett; 2011 Mar; 491(2):104-7. PubMed ID: 21232580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.
    Tzschentke TM; Christoph T; Kögel BY
    CNS Drugs; 2014 Apr; 28(4):319-29. PubMed ID: 24578192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.
    Tzschentke TM; Jahnel U; Kogel B; Christoph T; Englberger W; De Vry J; Schiene K; Okamoto A; Upmalis D; Weber H; Lange C; Stegmann JU; Kleinert R
    Drugs Today (Barc); 2009 Jul; 45(7):483-96. PubMed ID: 19834626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?
    Caraci F; Coluzzi F; Marinangeli F; Mercadante S; Rinonapoli G; Romualdi P; Nicora M; Dickenson AH
    Curr Med Res Opin; 2020 Jun; 36(6):1015-1024. PubMed ID: 32216591
    [No Abstract]   [Full Text] [Related]  

  • 16. Tapentadol prolonged release in fragile geriatric patients > 70 years with chronic severe musculoskeletal pain: an open-label, prospective, observational study.
    Aurilio C
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):40-44. PubMed ID: 31755085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
    Candiotti KA; Gitlin MC
    Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapentadol hydrochloride: a centrally acting oral analgesic.
    Wade WE; Spruill WJ
    Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology update: tapentadol for neuropathic pain.
    Pierce DM; Shipstone E
    Am J Hosp Palliat Care; 2012 Dec; 29(8):663-6. PubMed ID: 22310021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain.
    Christoph T; De Vry J; Tzschentke TM
    Neurosci Lett; 2010 Feb; 470(2):91-4. PubMed ID: 20026182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.